Significant Disparities in Access to Novel Agents For Patients With Melanoma
October 9th 2016Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Watch
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
October 9th 2016Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Watch
Results of the MONALEESA-2 Study in Advanced Breast Cancer
October 8th 2016Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.
Watch
Tools Available for Predicting Risk in Early Stage Lung Cancer
October 8th 2016Benjamin P. Levy, MD, medical director of thoracic medical oncology for Mount Sinai Health Systems and the associate medical director of the cancer clinical trials office for Mount Sinai Hospital, New York, discusses the tools currently available for predicting mortality risk in patients with early stage lung cancer.
Watch
Factors Associated With Discordance in Mutation Status in Metastatic CRC
October 8th 2016Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.
Watch
When to Perform a Prophylactic Bilateral Oophorectomy in Ovarian Cancer
October 7th 2016Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.
Watch